132 related articles for article (PubMed ID: 37886501)
21. An update on the CNS manifestations of neurofibromatosis type 2.
Coy S; Rashid R; Stemmer-Rachamimov A; Santagata S
Acta Neuropathol; 2020 Apr; 139(4):643-665. PubMed ID: 31161239
[TBL] [Abstract][Full Text] [Related]
22. Combination therapy with mTOR kinase inhibitor and dasatinib as a novel therapeutic strategy for vestibular schwannoma.
Sagers JE; Beauchamp RL; Zhang Y; Vasilijic S; Wu L; DeSouza P; Seist R; Zhou W; Xu L; Ramesh V; Stankovic KM
Sci Rep; 2020 Mar; 10(1):4211. PubMed ID: 32144278
[TBL] [Abstract][Full Text] [Related]
23. p21-Activated kinases are required for transformation in a cell-based model of neurofibromatosis type 2.
Chow HY; Stepanova D; Koch J; Chernoff J
PLoS One; 2010 Nov; 5(11):e13791. PubMed ID: 21072183
[TBL] [Abstract][Full Text] [Related]
24. Peroxynitrite supports a metabolic reprogramming in merlin-deficient Schwann cells and promotes cell survival.
Pestoni JC; Klingeman Plati S; Valdivia Camacho OD; Fuse MA; Onatunde M; Sparrow NA; Karajannis MA; Fernández-Valle C; Franco MC
J Biol Chem; 2019 Jul; 294(30):11354-11368. PubMed ID: 31171721
[TBL] [Abstract][Full Text] [Related]
25. Clinical features of spinal schwannomas in 65 patients with schwannomatosis compared with 831 with solitary schwannomas and 102 with neurofibromatosis Type 2: a retrospective study at a single institution.
Li P; Zhao F; Zhang J; Wang Z; Wang X; Wang B; Yang Z; Yang J; Gao Z; Liu P
J Neurosurg Spine; 2016 Jan; 24(1):145-54. PubMed ID: 26407091
[TBL] [Abstract][Full Text] [Related]
26. Neuregulin and laminin stimulate phosphorylation of the NF2 tumor suppressor in Schwann cells by distinct protein kinase A and p21-activated kinase-dependent pathways.
Thaxton C; Lopera J; Bott M; Fernandez-Valle C
Oncogene; 2008 Apr; 27(19):2705-15. PubMed ID: 17998937
[TBL] [Abstract][Full Text] [Related]
27. Rac1 is required for Prkar1a-mediated Nf2 suppression in Schwann cell tumors.
Manchanda PK; Jones GN; Lee AA; Pringle DR; Zhang M; Yu L; La Perle KM; Kirschner LS
Oncogene; 2013 Jul; 32(30):3491-9. PubMed ID: 23045281
[TBL] [Abstract][Full Text] [Related]
28. CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.
Widemann BC; Acosta MT; Ammoun S; Belzberg AJ; Bernards A; Blakeley J; Bretscher A; Cichowski K; Clapp DW; Dombi E; Evans GD; Ferner R; Fernandez-Valle C; Fisher MJ; Giovannini M; Gutmann DH; Hanemann CO; Hennigan R; Huson S; Ingram D; Kissil J; Korf BR; Legius E; Packer RJ; McClatchey AI; McCormick F; North K; Pehrsson M; Plotkin SR; Ramesh V; Ratner N; Schirmer S; Sherman L; Schorry E; Stevenson D; Stewart DR; Ullrich N; Bakker AC; Morrison H
Am J Med Genet A; 2014 Mar; 164A(3):563-78. PubMed ID: 24443315
[TBL] [Abstract][Full Text] [Related]
29. PAK1 inhibition reduces tumor size and extends the lifespan of mice in a genetically engineered mouse model of Neurofibromatosis Type 2 (NF2).
Hawley E; Gehlhausen J; Karchugina S; Chow HY; Araiza-Olivera D; Radu M; Smith A; Burks C; Jiang L; Li X; Bessler W; Masters A; Edwards D; Burgin C; Jones D; Yates C; Clapp DW; Chernoff J; Park SJ
Hum Mol Genet; 2021 Aug; 30(17):1607-1617. PubMed ID: 34075397
[TBL] [Abstract][Full Text] [Related]
30. mTORC1 inhibition delays growth of neurofibromatosis type 2 schwannoma.
Giovannini M; Bonne NX; Vitte J; Chareyre F; Tanaka K; Adams R; Fisher LM; Valeyrie-Allanore L; Wolkenstein P; Goutagny S; Kalamarides M
Neuro Oncol; 2014 Apr; 16(4):493-504. PubMed ID: 24414536
[TBL] [Abstract][Full Text] [Related]
31. A Xenograft Model of Vestibular Schwannoma and Hearing Loss.
Dinh CT; Bracho O; Mei C; Bas E; Fernandez-Valle C; Telischi F; Liu XZ
Otol Neurotol; 2018 Jun; 39(5):e362-e369. PubMed ID: 29557843
[TBL] [Abstract][Full Text] [Related]
32. [Pathogenesis and molecular pathology of vestibular schwannoma].
Brodhun M; Stahn V; Harder A
HNO; 2017 May; 65(5):362-372. PubMed ID: 27421984
[TBL] [Abstract][Full Text] [Related]
33. The role of insulin-like growth factors signaling in merlin-deficient human schwannomas.
Ammoun S; Schmid MC; Ristic N; Zhou L; Hilton D; Ercolano E; Carroll C; Hanemann CO
Glia; 2012 Nov; 60(11):1721-33. PubMed ID: 22821509
[TBL] [Abstract][Full Text] [Related]
34. Merlin status regulates p75(NTR) expression and apoptotic signaling in Schwann cells following nerve injury.
Ahmad I; Fernando A; Gurgel R; Jason Clark J; Xu L; Hansen MR
Neurobiol Dis; 2015 Oct; 82():114-122. PubMed ID: 26057084
[TBL] [Abstract][Full Text] [Related]
35. The p53/mouse double minute 2 homolog complex deregulation in merlin-deficient tumours.
Ammoun S; Schmid MC; Zhou L; Hilton DA; Barczyk M; Hanemann CO
Mol Oncol; 2015 Jan; 9(1):236-48. PubMed ID: 25217104
[TBL] [Abstract][Full Text] [Related]
36. Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells.
Lee TX; Packer MD; Huang J; Akhmametyeva EM; Kulp SK; Chen CS; Giovannini M; Jacob A; Welling DB; Chang LS
Eur J Cancer; 2009 Jun; 45(9):1709-20. PubMed ID: 19359162
[TBL] [Abstract][Full Text] [Related]
37. Validation of Bromodomain and Extraterminal proteins as therapeutic targets in neurofibromatosis type 2.
Doherty J; Mandati V; González Rodriguez MA; Troutman S; Shepard A; Harbaugh D; Brody R; Miller DC; Kareta MS; Kissil JL
Neurooncol Adv; 2022; 4(1):vdac072. PubMed ID: 35855490
[TBL] [Abstract][Full Text] [Related]
38. Point mutation in the NF2 gene of HEI-193 human schwannoma cells results in the expression of a merlin isoform with attenuated growth suppressive activity.
Lepont P; Stickney JT; Foster LA; Meng JJ; Hennigan RF; Ip W
Mutat Res; 2008 Jan; 637(1-2):142-51. PubMed ID: 17868749
[TBL] [Abstract][Full Text] [Related]
39. Merlin-deficient human tumors show loss of contact inhibition and activation of Wnt/β-catenin signaling linked to the PDGFR/Src and Rac/PAK pathways.
Zhou L; Ercolano E; Ammoun S; Schmid MC; Barczyk MA; Hanemann CO
Neoplasia; 2011 Dec; 13(12):1101-12. PubMed ID: 22247700
[TBL] [Abstract][Full Text] [Related]
40. Group I Paks as therapeutic targets in NF2-deficient meningioma.
Chow HY; Dong B; Duron SG; Campbell DA; Ong CC; Hoeflich KP; Chang LS; Welling DB; Yang ZJ; Chernoff J
Oncotarget; 2015 Feb; 6(4):1981-94. PubMed ID: 25596744
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
